ºÐÀÚÁø´Ü ½ÃÀå : ¾÷°è µ¿Çâ°ú ¼¼°è ¿¹Ãø - °Ë»ç À¯Çüº°, ¿ÀÆÛ¸µ À¯Çüº°, »ùÇà À¯Çüº°, ±â¼ú À¯Çüº°, Ä¡·á ¿µ¿ªº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Molecular Diagnostics Market: Industry Trends and Global Forecasts - Distribution by Test Type, Type of Offering, Type of Sample, Type of Technology, Therapeutic Area, End Users, and Geographical Regions
»óǰÄÚµå : 1762523
¸®¼­Ä¡»ç : Roots Analysis
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 224 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,799 £Ü 6,650,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,999 £Ü 9,699,000
PDF (One-Location Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ Æ¯Á¤ »ç¾÷ ºÎ¹®¿¡ ¼ÓÇÑ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,599 £Ü 14,688,000
PDF (Department License) help
PDF º¸°í¼­¸¦ ºÎ¼­ ´ÜÀ§·Î 12¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,999 £Ü 24,943,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ºÐÀÚÁø´Ü ½ÃÀå : °³¿ä

¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð´Â 2035³â±îÁöÀÇ ¿¹Ãø ±â°£ Áß 6.2%ÀÇ CAGR·Î È®´ëÇϸç, ÇöÀç 159¾ï ´Þ·¯¿¡¼­ 2035³â±îÁö 309¾ï ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­¿¡¼­´Â ½ÃÀå ±Ô¸ð¿Í ±âȸ ºÐ¼®À» ´ÙÀ½°ú °°Àº ¸Å°³ º¯¼ö·Î ±¸ºÐÇÕ´Ï´Ù.

°Ë»ç À¯Çü

Á¦°ø Á¦Ç° À¯Çü

»ùÇà À¯Çü

±â¼ú À¯Çü

Ä¡·á ¿µ¿ª

ÃÖÁ¾»ç¿ëÀÚ

ÁÖ¿ä Áö¿ª

ºÐÀÚÁø´Ü ½ÃÀå : ¼ºÀå°ú µ¿Çâ

ºÐÀÚÁø´Ü °Ë»ç´Â À¯Àüü°ú ÇÁ·ÎÅ׿ÈÀÇ »ý¹°ÇÐÀû ¸¶Ä¿¸¦ ºÐ¼®ÇÏ´Â µ¥ »ç¿ëµÇ´Â ÷´Ü ±â¼ú ¹× ÅøÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü ¼Ö·ç¼ÇÀº Áúº´À» °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇϸç, À¯ÀüÀÚ ÀÌ»óÀ» ½Äº°Çϰí, °³Àκ° ¸ÂÃã Ä¡·á °èȹÀ» ¼¼¿ì´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ºÐÀÚÁø´Ü ºÐ¾ß¿¡¼­ »ç¿ëµÇ´Â ÁÖ¿ä ±â¼ú·Î´Â ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ, Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ µîÀÌ ÀÖÀ¸¸ç, PCRÀº ¹Ì·®ÀÇ DNA¿Í RNA¸¦ ÁõÆøÇÏ°í °ËÃâÇÒ ¼ö Àִ ƯÀ̼ºÀÌ ³ôÀº ±â¼úÀÎ ¹Ý¸é, NGS´Â Àüü À¯ÀüüÀÇ °í󸮷® ¿°±â¼­¿­ºÐ¼®À» °¡´ÉÄÉ ÇÕ´Ï´Ù. ÀÌó·³ ºÐÀÚÁø´Ü ¼Ö·ç¼ÇÀº ¾ÏÁúȯ, °¨¿°Áúȯ, À¯ÀüÀÚ °Ë»ç, ¸ÂÃãÀÇ·á µî ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº Áø´ÜÀÇ Á¤È®¼ºÀ» ³ôÀÌ°í ¸ÂÃãÇü Ä¡·á Àü·«À» °¡´ÉÇÏ°Ô Çϰí Áö¿øÇÔÀ¸·Î½á ±Ã±ØÀûÀ¸·Î Áø´Ü °á°ú¸¦ °³¼±ÇÏ°í °øÁß º¸°ÇÀ» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ÀÇ»ç°áÁ¤ÀÇ 70% ÀÌ»óÀÌ ÀÓ»ó °Ë»ç °á°ú¸¦ ±â¹ÝÀ¸·Î ÀÌ·ç¾îÁö°í ÀÖ´Ù´Â »ç½ÇÀº ȯÀÚ Ä¡·á¿¡¼­ ÀÌ·¯ÇÑ Áø´Ü ÅøÀÌ ¾ó¸¶³ª Áß¿äÇÑÁö¸¦ ¹Ý¿µÇÕ´Ï´Ù.

Molecular Diagnostics Market-IMG1

¶ÇÇÑ ºÐÀÚÁø´Ü ¼Ö·ç¼ÇÀÌ Á¦°øÇÏ´Â ºü¸¥ °Ë»ç, ½Ã°£ ´ÜÃà, ½Å¼ÓÇÑ ÀÇ»ç°áÁ¤ µî ¿©·¯ °¡Áö ÀåÁ¡À¸·Î ÀÎÇØ ½ÃÀåÀº ¿¹Ãø ±â°£ Áß °ÇÀüÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÐÀÚÁø´Ü ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

ÀÌ º¸°í¼­´Â ºÐÀÚÁø´Ü ½ÃÀåÀÇ ÇöȲÀ» Á¶»çÇϰí ÀáÀçÀûÀÎ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÕ´Ï´Ù. ÀÌ º¸°í¼­ÀÇ ÁÖ¿ä Á¶»ç °á°ú´Â ´ÙÀ½°ú °°½À´Ï´Ù.

Molecular Diagnostics Market-IMG2
Molecular Diagnostics Market-IMG3

ºÐÀÚÁø´Ü ½ÃÀå : ÁÖ¿ä ºÎ¹®

°Ë»ç À¯Çü¿¡ µû¶ó ½ÃÀåÀº ½ÇÇè½Ç °Ë»ç¿Í ÇöÀå °Ë»ç·Î ±¸ºÐµË´Ï´Ù. ÇöÀç ºÐÀÚÁø´Ü ½ÃÀå¿¡¼­ ½ÇÇè½Ç °Ë»ç ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¾ÕÀ¸·Îµµ º¯ÇÏÁö ¾ÊÀ» °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ ÇöÀå °Ë»ç ºÐ¾ßÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀº ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº ½ÃÀå ¼ºÀå ÀáÀç·ÂÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â ½Ã¾àÀÌ ¼¼°è ºÐÀÚÁø´Ü ½ÃÀå¿¡¼­ °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

½Ã¾à, ±â±â, ¼­ºñ½º·Î ±¸ºÐµË´Ï´Ù. ÇöÀç ½Ã¾à ºÎ¹®Àº ¼¼°è ºÐÀÚÁø´Ü ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Ã¾àÀº ºó¹øÇÑ º¸ÃæÀÌ ÇÊ¿äÇϸç, ÀÌ´Â °æ»ó ¸ÅÃâ¿¡ ±â¿©ÇϹǷΠ½Ã¾à ºÎ¹®Àº ¿¹Ãø ±â°£ Áß ´õ ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

»ùÇà À¯Çü¿¡ µû¶ó ½ÃÀåÀº Ç÷¾×, Ç÷û ¹× Ç÷Àå, ¼Òº¯, ±âŸ °Ëü·Î ±¸ºÐµË´Ï´Ù. ÇöÀç Ç÷¾×, Ç÷û ¹× Ç÷Àå ºÎ¹®ÀÌ ¼¼°è ºÐÀÚÁø´Ü ½ÃÀå¿¡¼­ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¼Òº¯ ºÎ¹®Àº ¿¹Ãø ±â°£ Áß ´õ ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±â¼ú À¯Çüº°·Î ½ÃÀåÀº ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR), in situ hybridization, µî¿ÂÇÙ»êÁõÆø±â¼ú, Â÷¼¼´ë ½ÃÄö½Ì, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, Áú·®ºÐ¼®, ±âŸ·Î ±¸ºÐµË´Ï´Ù. ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) ºÐ¾ß°¡ Àüü ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÌ µÉ °ÍÀ¸·Î ¿¹»óµÇÁö¸¸, Â÷¼¼´ë ½ÃÄö½Ì ºÐ¾ßÀÇ ¼¼°è ºÐÀÚÁø´Ü ½ÃÀåÀÌ »ó´ëÀûÀ¸·Î ³ôÀº CAGR·Î ¼ºÀåÇÒ °¡´É¼ºÀÌ ³ô´Ù´Â Á¡Àº ÁÖ¸ñÇÒ ¸¸ÇÕ´Ï´Ù. ÀÌ´Â ³ôÀº 󸮷®, Á¤È®µµ Çâ»ó, ¿©·¯ À¯ÀüÀÚÀÇ µ¿½Ã ¿°±â¼­¿­ ºÐ¼® ±â´É µî Â÷¼¼´ë ½ÃÄö¼­°¡ Á¦°øÇÏ´Â ¸î °¡Áö ÀåÁ¡¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

½ÃÀåÀº Ä¡·á ¿µ¿ªº°·Î ½ÉÇ÷°üÁúȯ, À¯ÀüÁúȯ, °¨¿°Áúȯ, ½Å°æÁúȯ, Á¾¾çÁúȯ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. ÇöÀç °¨¿°Áúȯ ºÐ¾ß°¡ ºÐÀÚÁø´Ü ÀǾàǰ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Å°æÁúȯ ºÎ¹®Àº ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº ¼ºÀå ÀáÀç·ÂÀ» º¸ÀÌ¸ç ´Ù¸¥ ºÎ¹®¿¡ ºñÇØ ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î ¼¼°è ½ÃÀåÀº º´¿ø, ¿¬±¸¼Ò, ±âŸ·Î ±¸ºÐµË´Ï´Ù. ÇöÀç º´¿ø ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÇÇè½Ç¿ë ºÐÀÚÁø´Ü ½ÃÀåÀº ÇâÈÄ ¼ö³â°£ Å« ÆøÀÇ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

ÁÖ¿ä Áö¿ªº°·Î ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾Æ, ¾Æ½Ã¾Æ, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«·Î ±¸ºÐµË´Ï´Ù. ÇöÀç ºÏ¹Ì°¡ ¼¼°è ºÐÀÚÁø´Ü ÀǾàǰ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ÇâÈÄ ´õ ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÐÀÚÁø´Ü ½ÃÀåÀÇ Âü¿© ±â¾÷ ¿¹

¸ñÂ÷

Á¦1Àå ¹è°æ

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °æÁ¦Àû ¹× ±âŸ ÇÁ·ÎÁ§Æ® ƯÀ¯ °í·Á »çÇ×

Á¦4Àå °³¿ä

Á¦5Àå ¼­·Ð

Á¦6Àå ½ÃÀå ¿µÇ⠺м® : ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, °úÁ¦

Á¦7Àå ¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå

Á¦8Àå ºÐÀÚÁø´Ü ½ÃÀå(°Ë»ç À¯Çüº°)

Á¦9Àå ºÐÀÚÁø´Ü ½ÃÀå(¿ÀÆÛ¸µ À¯Çüº°)

Á¦10Àå ºÐÀÚÁø´Ü ½ÃÀå(»ùÇà À¯Çüº°)

Á¦11Àå ºÐÀÚÁø´Ü ½ÃÀå(±â¼úº°)

Á¦12Àå ºÐÀÚÁø´Ü ½ÃÀå(Ä¡·á ¿µ¿ªº°)

Á¦13Àå ºÐÀÚÁø´Ü ½ÃÀå(ÃÖÁ¾»ç¿ëÀÚº°)

Á¦14Àå ºÐÀÚÁø´Ü ½ÃÀå(Áö¿ªº°)

Á¦15Àå ºÐÀÚÁø´Ü ½ÃÀå(ÁÖ¿ä ±â¾÷º°)

Á¦16Àå ½ÃÀå °³¿ä : ÁÖ¿ä ºÐÀÚÁø´Ü ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ

Á¦17Àå ±â¾÷ °æÀï·Â ºÐ¼® : ºÐÀÚÁø´Ü ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ

Á¦18Àå ±â¾÷ °³¿ä : ºÏ¹Ì¿¡ º»»ç¸¦ µÐ ºÐÀÚÁø´Ü ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ

Á¦19Àå ±â¾÷ °³¿ä : À¯·´¿¡ º»»ç¸¦ µÐ ºÐÀÚÁø´Ü ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ

Á¦20Àå ±â¾÷ °³¿ä : ¾Æ½Ã¾Æ¿¡ º»»ç¸¦ µÐ ºÐÀÚÁø´Ü ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ

Á¦21Àå Porter's Five Forces ºÐ¼®

Á¦22Àå ºÎ·Ï I : Ç¥Çü½Ä µ¥ÀÌÅÍ

Á¦23Àå ºÎ·Ï II : ±â¾÷ ¹× Á¶Á÷ ¸®½ºÆ®

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

MOLECULAR DIAGNOSTICS MARKET: OVERVIEW

As per Roots Analysis, the global molecular diagnostics market is estimated to grow from USD 15.9 billion in the current year to USD 30.9 billion by 2035, at a CAGR of 6.2% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Test Type

Type of Offering

Type of Sample

Type of Technology

Therapeutic Area

End Users

Key Geographical Regions

MOLECULAR DIAGNOSTICS MARKET: GROWTH AND TRENDS

Molecular diagnostic tests are advanced techniques and tools used to analyze biological markers in the genome and proteome. These diagnostic solutions are essential for detecting and monitoring diseases, identifying genetic abnormalities, and guiding personalized treatment plans. The primary technologies used in the molecular diagnostics domain include polymerase chain reaction, next-generation sequencing and microarrays. While PCR is a highly specific technique that enables the amplification and detection of trace amounts of DNA or RNA, NGS allows for high-throughput sequencing of entire genomes. Thus, molecular diagnostic solutions are pivotal across various medical fields, including oncological disorders, infectious diseases, genetic testing, and personalized medicine. These solutions enhance the accuracy of diagnosis, enable and support tailored treatment strategies aiming to ultimately improve diagnostic outcomes and advancing public health. In addition, it is worth mentioning that more than 70% of the healthcare decisions are made based on laboratory test results, which reflects the importance of such diagnostic tools in patient care.

Molecular Diagnostics Market - IMG1

Further, owing to the several benefits offered by these molecular diagnostic solutions, such as providing rapid testing, reducing turnaround times and enabling quicker decision-making, the market is expected to grow at a healthy compounded annual growth rate (CAGR) during the forecast period.

MOLECULAR DIAGNOSTICS MARKET: KEY INSIGHTS

The report delves into the current state of the molecular diagnostics market and identifies potential growth opportunities within industry. Some key findings from the report include:

Molecular Diagnostics Market - IMG2
Molecular Diagnostics Market - IMG3

MOLECULAR DIAGNOSTICS MARKET: KEY SEGMENTS

Laboratory Testing Segment holds the Largest Share of the Molecular Diagnostics Market

Based on the test type, the market is segmented into laboratory testing and point-of-care testing. At present, the laboratory testing segment holds the maximum share of the molecular diagnostics market. This trend is likely to remain the same in the coming future. Further, the molecular diagnostics market for point-of-care testing segment is expected to show the highest market growth potential during the forecast period.

By Type of Offering, Reagents is the Fastest Growing Segment of the Global Molecular Diagnostics Market

Based on the type of offering, the market is segmented into reagents, instruments and services. At present, the reagents segment holds the maximum share of the global molecular diagnostics market. Further, owing to the fact that reagents are required to be replenished frequently, which contributes to the recurrent revenues, the market for reagents segment is expected to grow at a higher CAGR during the forecast period.

By Type of Sample, Blood, Serum and Plasma Segment Accounts for the Largest Share of the Global Molecular Diagnostics Market

Based on the type of sample, the market is segmented into blood, serum and plasma, urine, and other samples. Currently, the blood, serum and plasma segment capture the highest proportion of the global molecular diagnostics market. However, the urine segment is expected to grow at a higher CAGR during the forecast period.

The Polymerase Chain Reaction (PCR) Segment by Type of Technology Occupy the Largest Share of the Molecular Diagnostics Market

Based on the type of technology, the market is segmented into Polymerase Chain Reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology, next generation sequencing, microarrays, mass spectrometry and others. While the polymerase chain reaction (PCR) segment is expected to be the primary driver of the overall market, it is worth highlighting that the global molecular diagnostics market for next generation sequencing segment is likely to grow at a relatively higher CAGR. This can be attributed to the several benefits offered by next generation sequencing, such as high-throughput, improved accuracy, and the capability to simultaneously sequence multiple genes.

By Therapeutic Area, Infectious Disease Segment is Likely to Dominate the Molecular Diagnostics Market

Based on the therapeutic area, the market is segmented into cardiovascular diseases, genetic diseases, infectious diseases, neurological diseases, oncological diseases and others. At present the infectious diseases segment holds the maximum share of the molecular diagnostics market. Additionally, the neurological diseases segment is expected to show the highest growth potential during the forecast period, growing at a higher CAGR, compared to the other segments.

Currently, Hospitals Segment Holds the Largest Share of the Molecular Diagnostics Market

Based on end users, the global market is segmented into hospitals, laboratories, and others. Currently, the hospitals segment holds the largest market share. However, the molecular diagnostics market for laboratories segment is expected to witness substantial growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World. Currently, North America dominates the global molecular diagnostics market and accounts for the largest revenue share. Further, the market in Asia-Pacific is likely to grow at a higher CAGR in the coming future.

Example Players in the Molecular Diagnostics Market

MOLECULAR DIAGNOSTICS MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. BACKGROUND

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

7. GLOBAL MOLECULAR DIAGNOSTICS MARKET

8. MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE

9. MOLECULAR DIAGNOSTICS MARKET, BY TYPE OF OFFERING

10. MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

11. MOLECULAR DIAGNOSTICS MARKET, BY TYPE OF TECHNOLOGY

12. MOLECULAR DIAGNOSTICS MARKET, BY THERAPEUTIC AREA

13. MOLECULAR DIAGNOSTICS MARKET, BY END USERS

14. MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHICAL REGIONS

15. MOLECULAR DIAGNOSTICS MARKET, BY LEADING PLAYERS

16. MARKET OVERVIEW: LEADING MOLECULAR DIAGNOSTIC SOLUTION PROVIDERS

17. COMPANY COMPETITIVENESS ANALYSIS: MOLECULAR DIAGNOSTIC SOLUTION PROVIDERS

18. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN NORTH AMERICA

19. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN EUROPE

20. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN ASIA

21. PORTER'S FIVE FORCES ANALYSIS

22. APPENDIX I: TABULATED DATA

23. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â